The U.S. Food and Drug Administration has approved British drugmaker GSK's asthma drug to treat some patients with a chronic ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud.

GSK (LSE:GSK) recently received FDA approval for Nucala for COPD treatment, potentially enhancing its market presence.

The U.S. Food and Drug Administration has approved GSK plc (NYSE: GSK )’s asthma medication, Nucala, for expanded use in ...

Britain's GSK and drug developer iTeos Therapeutics said on Tuesday they have stopped developing an experimental lung cancer ...

GSK Plc won US approval for its drug to treat a deadly lung disease, ramping up competition with rival Sanofi.

GSK’s blockbuster respiratory drug Nucala was approved Thursday for certain patients with chronic obstructive pulmonary ...

GSK has gained approval from the US Food and Drug Administration (FDA) for its monoclonal antibody, Nucala (mepolizumab), as ...

GSK (GSK) stock in focus as its antibody drug conjugate Blenrep gains EMA recommendation for relapsed multiple myeloma with ...

GSK plans to purchase an experimental drug for the liver disease MASH from Boston Pharmaceuticals for $1.2 billion upfront.

The COPD approval marks the fifth Nucala has received from the FDA, following green lights in severe asthma, chronic rhinosinusitis with nasal polyps, eosinophilic granulomatosis with polyangiitis and ...

The U.S. Food and Drug Administration has approved British drugmaker GSK's asthma drug to treat some patients with a chronic ...